60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded to Sell at Wall Street Zen

60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

A number of other research firms also recently issued reports on SXTP. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, December 29th. HC Wainwright lifted their price objective on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, Ascendiant Capital Markets lowered their price objective on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating for the company in a research note on Friday, November 28th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 60 Degrees Pharmaceuticals currently has an average rating of “Hold” and an average target price of $17.60.

60 Degrees Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:SXTP opened at $1.95 on Friday. The business’s 50 day moving average is $3.12 and its 200 day moving average is $4.12. The stock has a market cap of $2.07 million, a P/E ratio of -0.14 and a beta of 3.01. 60 Degrees Pharmaceuticals has a 52-week low of $1.36 and a 52-week high of $17.68.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.